Abbott completes acquisition of Exact Sciences
Rhea-AI Summary
Abbott (NYSE: ABT) completed its acquisition of Exact Sciences on March 23, 2026, making Exact Sciences a wholly owned Abbott subsidiary and ending Exact Sciences' Nasdaq trading on March 20, 2026.
The deal adds a comprehensive cancer screening and precision oncology portfolio — including Cologuard, Oncotype DX, Oncodetect and Cancerguard — and positions Abbott to serve millions more and lead in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.
Positive
- Acquisition completed, Exact Sciences is now an Abbott wholly owned subsidiary
- Portfolio expansion with Cologuard, Oncotype DX, Oncodetect and Cancerguard
- Market leadership in a fast-growing $60 billion U.S. cancer screening and precision oncology market
- Scale to reach millions of additional patients through Abbott's global footprint
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ABT is down 1.61% while key device peers show mixed, mostly modest declines: BSX, SYK, MDT and SNN are slightly negative, but EW is up 0.78%, pointing to a stock-specific reaction rather than a broad sector move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 20 | Acquisition announcement | Positive | -1.7% | Abbott agrees to acquire Exact Sciences for $105 per share in cash. |
| Feb 20 | Shareholder approval | Positive | +2.7% | Exact Sciences stockholders approve cash acquisition by Abbott. |
Acquisition headlines have produced mixed reactions, with one positive and one negative move despite broadly strategic messaging.
Over the past months, Abbott has advanced a multi-step acquisition of Exact Sciences. On Nov 20, 2025, it agreed to acquire Exact Sciences for $105 per share, implying about $21 billion equity value, which was followed by a modest share decline. On Feb 20, 2026, Exact stockholders approved the deal, and Abbott shares rose. Today’s completion announcement continues this acquisition timeline and solidifies Abbott’s expansion in cancer screening and precision oncology diagnostics.
Historical Comparison
In the last two acquisition-related headlines, ABT’s average 1-day move was 0.51%, with one positive and one negative reaction, underscoring inconsistent trading responses to this deal.
Acquisition news has progressed from the initial agreement, to Exact Sciences shareholder approval, and now to formal closing of the transaction.
Regulatory & Risk Context
Abbott has an effective Form S-3ASR shelf prospectus dated Feb 23, 2026, allowing it to offer debt securities, common and preferred shares, depositary shares, warrants, purchase contracts and units from time to time. This framework provides flexibility to raise capital or refinance through various securities, which can affect capital structure and potential dilution depending on how it is used.
Market Pulse Summary
This announcement finalizes Abbott’s acquisition of Exact Sciences, making it a leader in fast‑growing cancer screening and precision oncology diagnostics and targeting a $60 billion U.S. segment. Historical acquisition milestones show varied share reactions, underscoring execution and integration as key watch points. Abbott also maintains an effective S-3ASR shelf registration, giving flexibility to issue various securities. Investors may track how added products like Cologuard and Oncotype DX contribute to growth and margins over time.
Key Terms
precision oncology diagnostics medical
molecular residual disease medical
mrD medical
multi-cancer early detection medical
AI-generated analysis. Not financial advice.
- Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments
- Advances Abbott's mission to make healthcare more accessible and give people more control over their health
ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people.
"Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments," said Robert B. Ford, chairman and chief executive officer, Abbott. "With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care."
Pursuant to the terms of the merger agreement, upon completion of the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott. As a result of the completion of the acquisition, March 20, 2026, was the last day of trading of Exact Sciences shares on the Nasdaq Stock Market.
Strategic fit
The transaction positions Abbott to advance diagnostics that are more preventative, predictive and personalized while expanding the company's presence in one of the fastest-growing areas of healthcare as global cancer incidence continues to rise. It also adds a new growth vertical to Abbott's already high-single-digit growth expectations, establishing leadership in the fast-growing
Industry-leading offerings and pipeline
Abbott now has a comprehensive suite of products and differentiated pipeline focused on the early detection of cancer and supporting personalized treatments. This includes the Cologuard® test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX®, which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect®, a tumor-informed molecular residual disease (MRD) test to help identify cancer recurrence and guide follow-up care; and Cancerguard®, a multi-cancer early detection blood test.
Abbott also adds a leading pipeline of next-generation cancer screening and diagnostics designed to detect cancer even earlier, optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage the disease.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
This communication contains forward-looking statements about, among other things, the acquisition of Exact Sciences by Abbott. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the ability of Abbott to successfully integrate Exact Sciences' operations; the ability of Abbott to implement its plans, forecasts and other expectations with respect to Exact Sciences' business after the completion of the transaction; and risks related to the ability of Abbott to realize the anticipated synergies and benefits of the transaction, including the possibility that the expected synergies and benefits from the transaction will not be realized or will not be realized within the expected time period.
You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Abbott and Exact Sciences described in the "Risk Factors" section in each of Abbott's Annual Report on Form 10- K for the year ended December 31, 2025, and Exact Sciences' Annual Report on Form 10-K for the year ended December 31, 2025, respectively, and their respective other reports filed with the SEC. Free copies of these documents may be obtained from the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abbott undertakes no obligation, and does not intend, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments or otherwise, except as required by law.
View original content:https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-exact-sciences-302722046.html
SOURCE Abbott
FAQ
When did Abbott (ABT) complete the acquisition of Exact Sciences and what changed on the stock market?
Which Exact Sciences products did Abbott (ABT) add through the March 2026 acquisition?
How does the Exact Sciences acquisition affect Abbott's position in cancer diagnostics (ABT)?
Will Abbott (ABT) reach more patients after buying Exact Sciences?
What types of tests did Abbott (ABT) acquire from Exact Sciences in March 2026?
How does the Exact Sciences deal affect Abbott's growth outlook (ABT)?
